Full Year 2025 Vimian Group AB Earnings Call Transcript
Key Points
- Vimian Group AB (VIMGF) delivered a revenue growth of 13% and adjusted EBITDA growth of 11% for the full year 2025.
- The company achieved a strong operational cash flow of €105.7 million, corresponding to a cash conversion of 101%.
- Vimian Group AB (VIMGF) completed a successful list change to the NASDAQ main market, now classified as a large-cap company.
- The specialty pharma segment showed positive performance with 6% organic growth in Q4, driven by innovation and cross-sales activities.
- The company expanded its M&A pipeline with three acquisitions in Q4, enhancing its portfolio and geographic footprint.
- The Medtech Orthopedics segment faced headwinds, particularly in the US, and is not expected to deliver year-on-year growth until later in spring 2026.
- Currency movements, especially involving the US dollar, negatively impacted revenue growth by 4% in Q4.
- The departure of the head of specialty pharma, Magnus, after 10 years, may pose transitional challenges despite a strong transition plan.
- The diagnostic business reported a decline in adjusted EBITDA by 3% for the full year, despite a 9% revenue growth.
- The company is undergoing significant changes in its US Medtech business, with a new sales team and product portfolio rationalization, which may affect short-term performance.
Welcome to the Vivian Group Q4 report 2025 presentation. During the Q&A session, participants are able to ask questions by dialing 5 on their telephone keypad. Now I will hand the conference over to the speakers, CEO Aloreza Tajbas and CFO Carl Johann Zetterberg Baudry. Please go ahead.
Good morning everyone, and welcome to Vimien's 2025 year end and fourth quarter earnings call. I'm Molly Taibach, the new group CEO since the end of last year after leading the veterinary service segment for the past 4 years.
To give you some background, during my 4 years as head of veterinary services, the business developed from a Northern European purchasing organization into a global service platform with over 10,000 member clinics.
I've personally experienced Vivian's ability to attract talent and entrepreneurs and take something relative, relatively small with potential and build it into global scale and a market leader.
I'm a firm believer in our strategy of organic and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
